Ocera Therapeutics, Inc. (NASDAQ:OCRX) was downgraded by research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research note issued on Friday, November 3rd, Marketbeat reports. They presently have a $1.75 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 1.74% from the company’s previous close.
Separately, Zacks Investment Research downgraded Ocera Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $1.69.
Ocera Therapeutics (NASDAQ:OCRX) traded down $0.02 during trading hours on Friday, hitting $1.72. The stock had a trading volume of 320,868 shares, compared to its average volume of 1,141,249. Ocera Therapeutics has a twelve month low of $0.52 and a twelve month high of $2.95.
A hedge fund recently raised its stake in Ocera Therapeutics stock. Hikari Power Ltd boosted its holdings in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 50.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 376,596 shares of the biopharmaceutical company’s stock after purchasing an additional 126,596 shares during the period. Hikari Power Ltd owned about 1.42% of Ocera Therapeutics worth $437,000 as of its most recent filing with the Securities and Exchange Commission. 18.54% of the stock is currently owned by institutional investors and hedge funds.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with our FREE daily email newsletter.